Castleman disease: clinical features, pathology, and treatment outcomes in 12 cases
-
By
-
Yi Gong
-
Huiyang Liu
-
Yuanlong Li
-
Xin Wang
-
Jie Yuan
-
Jianming Wang
-
July 16, 2026
Clinical Scorecard: Clinical Characteristics, Pathological Insights, and Treatment Results of Castleman Disease: A Study of 12 Cases
At a Glance
| Category | Detail |
|---|
| Condition | Castleman Disease |
| Key Mechanisms | Lymphoproliferative disorder characterized by abnormal lymphoid tissue proliferation. |
| Target Population | Patients diagnosed with Castleman disease in a regional Chinese population. |
| Care Setting | Regional medical centers |
Key Highlights
- 12 patients analyzed, median age 45 years, predominantly male.
- 7 patients diagnosed with unicentric CD (UCD), 5 with multicentric CD (MCD).
- Complete surgical resection resulted in no recurrence for UCD patients.
- R-CHOP chemotherapy yielded favorable outcomes for MCD patients.
- Oral TCD regimen was effective for a refractory MCD case.
Guideline-Based Recommendations
Diagnosis
- Diagnosis confirmed via a three-step differential diagnosis protocol.
Management
- Complete surgical resection is curative for resectable UCD.
- MCD typically requires systemic therapy, with R-CHOP as a first-line alternative.
Monitoring & Follow-up
- Follow-up outcomes indicate no recurrence in treated patients.
Risks
- High misdiagnosis rates and delays in therapy due to disease heterogeneity.
Patient & Prescribing Data
Patients with Castleman disease diagnosed at Linyi People’s Hospital.
Individualized treatment approaches based on disease subtype and patient response.
Clinical Best Practices
- Utilize a systematic approach for diagnosis to reduce misdiagnosis.
- Consider R-CHOP as a viable treatment option in resource-limited settings.
Related Resources & Content
